Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Risk and Management of Intracerebral Hemorrhage in Patients With Bleeding Disorders Publisher Pubmed



Dorgalaleh A1 ; Farshi Y2 ; Haeri K3 ; Ghanbari OB1 ; Ahmadi A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Hematology and Blood Transfusion, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
  4. 4. Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, 66177-13446, Iran

Source: Seminars in Thrombosis and Hemostasis Published:2022


Abstract

Intracerebral hemorrhage (ICH) is the most dreaded complication, and the main cause of death, in patients with congenital bleeding disorders. ICH can occur in all congenital bleeding disorders, ranging from mild, like some platelet function disorders, to severe disorders such as hemophilia A, which can cause catastrophic hemorrhage. While extremely rare in mild bleeding disorders, ICH is common in severe coagulation factor (F) XIII deficiency. ICH can be spontaneous or trauma-related. Spontaneous ICH occurs more often in adults, while trauma-related ICH is more prevalent in children. Risk factors that can affect the occurrence of ICH include the type of bleeding disorder and its severity, genotype and genetic polymorphisms, type of delivery, and sports and other activities. Patients with hemophilia A; afibrinogenemia; FXIII, FX, and FVII deficiencies; and type 3 von Willebrand disease are more susceptible than those with mild platelet function disorders, FV, FXI, combined FV-FVIII deficiencies, and type 1 von Willebrand disease. Generally, the more severe the disorder, the more likely the occurrence of ICH. Contact sports and activities can provoke ICH, while safe and noncontact sports present more benefit than danger. An important risk factor is stressful delivery, whether it is prolonged or by vacuum extraction. These should be avoided in patients with congenital bleeding disorders. Familiarity with all risk factors of ICH can help prevent occurrence of this diathesis and reduce related morbidity and mortality. © 2022 ASTM International. All rights reserved.
Related Docs
View other Related Docs
1. Diagnosis, Clinical Manifestations and Management of Rare Bleeding Disorders in Iran, Hematology (2017)
2. Subarachnoid Hemorrhage in Congenital Factor X Deficiency: A Case Study and Literature Review, Iranian Red Crescent Medical Journal (2016)
3. A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency, Seminars in Thrombosis and Hemostasis (2019)
4. Spectrum of Factor X Gene Mutations in Iranian Patients With Congenital Factor X Deficiency, Blood Coagulation and Fibrinolysis (2016)
5. Guidelines for Laboratory Diagnosis of Factor Xiii Deficiency, Blood Coagulation and Fibrinolysis (2016)
6. Diagnosis of Factor Xiii Deficiency, Hematology (2016)
7. Expression and Cpg Island Methylation Pattern of Mmp-2 and Mmp-9 Genes in Patients With Congenital Factor Xiii Deficiency and Intracranial Hemorrhage, Hematology (United Kingdom) (2019)
8. Correlation Between Phenotype and Coagulation Factor Activity Level in Rare Bleeding Disorders: A Systematic Review, Seminars in Thrombosis and Hemostasis (2025)
Experts (# of related papers)
View all Related Experts
Shaban Alizadeh (10)
Gholamreza Toogeh (3)
Other Related Docs
9. Congenital Prothrombin Deficiency, Journal of Cellular and Molecular Anesthesia (2018)
10. Congenital Factor Ii Deficiency, Congenital Bleeding Disorders: Diagnosis and Management (2018)
11. Fibrinogen Aα Gene Genotyping in Patients With Inherited Afibrinogenemia Deficiency; a Novel Mutation in Iranian Afibrinogenemia Patients, Blood Coagulation and Fibrinolysis (2023)
12. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency, Clinical and Applied Thrombosis/Hemostasis (2015)
13. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor, Clinical and Applied Thrombosis/Hemostasis (2016)
14. Central Nervous System Bleeding in Pediatric Patients With Factor Xiii Deficiency: A Study on 23 New Cases, Hematology (2015)
15. Effect of Social Factors on the Highest Global Incidence of Congenital Factor Xiii Deficiency in Southeast of Iran, Archives of Iranian Medicine (2015)
16. Bleeding Episodes Among Patients With Congenital Fibrinogen Disorders, a Study on 12 New Iranian Patients, Journal of Cellular and Molecular Anesthesia (2018)
17. Von Willebrand Factor Neutralizing and Non-Neutralizing Alloantibodies in 213 Subjects With Type 3 Von Willebrand Disease Enrolled in 3Winters-Ips, Journal of Thrombosis and Haemostasis (2023)
18. Factor Xiii Deficiency in Iran: A Comprehensive Review of the Literature, Seminars in Thrombosis and Hemostasis (2015)
19. Expression and Methylation Status of Vascular Endothelial Growth Factor and Thrombospondin-1 Genes in Congenital Factor Xiii-Deficient Patients With Intracranial Hemorrhage, Blood Coagulation and Fibrinolysis (2021)
20. Coagulation Factor Xiii-A A614t Gene Variation Is Suggestive of Founder Effect in Iranian Patients With Sever Congenital Factor Xiii Deficiency, Journal of Cellular and Molecular Anesthesia (2016)
21. First Cases of Severe Congenital Factor Xiii Deficiency in Southwestern Afghanistan in the Vicinity of Southeast of Iran, Blood Coagulation and Fibrinolysis (2015)